monARC Bionetworks Announces Strategic Integration with Roivant Drug Development Platform to Accelerate Delivery of New Medicines

"Roivant's drug development team supports the companies in our family as they develop innovative medicines in their respective therapeutic areas," said William T. Symonds, PharmD, Chief Development Officer at Roivant. "monARC's capabilities will enhance the design and conduct of our own clinical trials, as well as trials conducted by other companies and institutions."

Roivant